awmsg logo



emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®)


Reference No. 2374

Publication date:
25/07/2014


Appraisal information

emtricitabine/rilpivirine/tenofovir disoproxil (as fumarate) (Eviplera®) 200 mg/25 mg/245 mg film-coated tablet


Company: Gilead Sciences Ltd
BNF category: Infections
NMG meeting date: 14/05/2014
AWMSG meeting date: 11/06/2014
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 1514
Ministerial ratification: 24/07/2014

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Emtricitabine/rilpivirine/tenofovir disoproxil (Eviplera®) is recommended as an option for use within NHS Wales for antiretroviral treatmentexperienced adults infected with human immunodeficiency virus type 1(HIV-1) without known mutations associated with resistance to the nonnucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with a viral load ≤ 100,000 HIV-1 RNA copies/ml. As with other antiretroviral medicinal products, genotypic resistance testing and/or historical resistance data should guide the use of Eviplera®.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download